Skip to content

Clinical Observation of Tai-Yi Moxibustion in the Treatment of Back Myofascitis

Clinical Observation of Tai-Yi Moxibustion in the Treatment of Back Myofascitis

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300076981
Enrollment
Unknown
Registered
2023-10-26
Start date
2023-10-26
Completion date
Unknown
Last updated
2023-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Back Muscle Tendon Fasciitis

Interventions

Test Group:Tai-Yi moxibustion
control group:diclofenac sodium gel for external application

Sponsors

Dongzhimen Hospital of Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria of traditional Chinese and western medicine for back myofascitis; (2) Meet the TCM syndrome differentiation standard of cold and dampness obstruction syndrome, qi stagnation and blood stasis syndrome; (3) Acute phase of myofasciitis and acute phase of chronic pain, the number of onset is <30 days, the course of disease is not limited; (4) The attack site is located in the thoracic and dorsal region, that is, the line from the 7th cervical spine to the two sides of the acromion is taken as the upper boundary, and the line from the 12th thoracic spine and the lower edge of the 12th costal to the front of the 11th rib is the next area of the spine and the rear and the soft tissues on both sides; (5) Pain VAS score: 0 <VAS <7; (6) No gender limit, age between 18 and 65 years old; (7) Did not take analgesic drugs or received other analgesic treatment in the last 2 weeks; (8) Voluntary participation and the signing of the informed consent form; All the above can be included

Exclusion criteria

Exclusion criteria: (1) Acute torticollis, severe spinal stenosis or spinal deformities, thoracic vertebral dislocation, spondylolisthesis, tumors, tuberculosis, fractures, mandatory spondylitis, rheumatic diseases, and back pain caused by other diseases. (2) Patients with combined upper gastrointestinal ulcers, history of bleeding, ischemic heart disease or cerebrovascular disease (perioperative period of coronary artery bypass grafting, history of stroke or ischemic attack), renal dysfunction, disorders of coagulation mechanisms (including the use of anticoagulants), and other serious life-threatening primary diseases such as heart, brain, liver, kidney, endocrine, and blood systems, as well as mental illness. (3) Pregnant and lactating women. (4) There are any contraindications to moxibustion, such as scars or infections on the moxibustion site, or researchers believe that the moxibustion site may cause Individuals with systemic diseases who are currently not suitable for taking measures. (5) Clinical researchers believe that participants in clinical studies cannot cooperate with therapists. (6) Participants in other research projects. Any one of the above shall be excluded.

Design outcomes

Primary

MeasureTime frame
McGill Pain Questionnaire Short-Form;

Secondary

MeasureTime frame
SF-36;

Countries

China

Contacts

Public ContactJiping Zhao

Dongzhimen Hospital of Beijing University of Chinese Medicine

zjp7883@sina.com+86 136 2138 2136

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026